J-P. Zellweger (Villars-Sur-Glâne, Switzerland), W. Yew (Hong Kong, Hong Kong)
Chloroquine as a potential adjunctive therapy in tuberculosis
U. Matt, R. Müller, D. Müller, A. Stenzinger, A. Zinkernagel, A. Seelig, J. Nemeth (Zürich, Basel, Switzerland; Heidelberg, Germany)
|   |
Impact of food intake on pharmacokinetics(PK) of first-line tuberculosis drugs in treatment-naive patients
A. M. Saktiawati, M. G. G. Sturkenboom, Sumardi, Y. W. Subronto, J. G. W. Kosterink, Y. Stienstra, J. W. C. Alffenaar, T. S. van der Werf (Yogyakarta, Indonesia; Groningen, Netherlands)
| |
Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis (M/XDR-TB): An open-label phase 1 safety trial
A. Skrahin, R. Ahmed, G. Ferrara, L. Rane, T. Poiret, Y. Isaikina, A. Skrahina, A. Zumla, M. Maeurer (Minsk, Belarus; Solna, Stockholm, Sweden; Perugia, Italy; London, United Kingdom)
| |
A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment
N. Clerk, R. Anandavelu, W. Dibble, G. Antunes (Middlesbrough, United Kingdom)
|  |
Liver injury in treatment of latent tuberculosis infection - is the age cut-off for treatment justified?
A. L. Gill, S. A. Leong, T. G. D. Capstick, J. P. Watson (Leeds, United Kingdom)
| |